FDA 483 - Nancy Kim, M.D. - March 25, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Nancy Kim, M.D., a clinical investigator in Scottsdale, AZ, revealed significant deviations from investigational plans and protocols. The investigator failed to personally conduct required study assessments, delegated duties to non-delegated staff, and allowed staff to use her login credentials for data entry. Additionally, the inspection found a dosing error involving an incorrect investigational product and a failure to report this and other dispensing errors to the sponsor in a timely manner.
ID · 745460e3-0f68-4b66-a1c0-5c3dcdb83709